Elevated Copeptin Levels Are Associated with Heart Failure Severity and Adverse Outcomes in Children with Cardiomyopathy
暂无分享,去创建一个
J. Towbin | A. West | Samir H. Shah | Karan B. Karki | A. Saini | S. Tadphale | R. Philip
[1] M. Hersberger,et al. Copeptin Release in Arterial Hypotension and Its Association with Severity of Disease in Critically Ill Children , 2022, Children.
[2] Doaa El Amrousy,et al. Predictive Value of Plasma Copeptin Level in Children with Acute Heart Failure , 2022, Pediatric Cardiology.
[3] A. Deniz,et al. Increased Circulating Copeptin Levels Are Associated with Vaso-Occlusive Crisis and Right Ventricular Dysfunction in Sickle Cell Anemia , 2021, Medical Principles and Practice.
[4] Hossam A. Hodeib,et al. Plasma copeptin levels in children with pulmonary arterial hypertension associated with congenital heart disease , 2021, European Journal of Pediatrics.
[5] S. Goldsmith. Arginine vasopressin antagonism in heart failure: Current status and possible new directions. , 2019, Journal of cardiology.
[6] H. Yamazawa,et al. Efficacy and safety of tolvaptan for pediatric patients with congestive heart failure. Multicenter survey in the working group of the Japanese Society of PEdiatric Circulation and Hemodynamics (J-SPECH). , 2016, International journal of cardiology.
[7] Z. Prohászka,et al. Copeptin (C-terminal pro arginine-vasopressin) is an independent long-term prognostic marker in heart failure with reduced ejection fraction. , 2015, Heart, lung & circulation.
[8] J. H. Lee,et al. Vasopressin and copeptin levels in children with sepsis and septic shock , 2013, Intensive Care Medicine.
[9] J. Towbin,et al. Prevalence, morbidity, and mortality of heart failure-related hospitalizations in children in the United States: a population-based study. , 2012, Journal of cardiac failure.
[10] I. Gustafsson,et al. Plasma copeptin levels and prediction of outcome in heart failure outpatients: relation to hyponatremia and loop diuretic doses. , 2012, Journal of cardiac failure.
[11] R. Ross. The Ross Classification for Heart Failure in Children After 25 Years: A Review and an Age-Stratified Revision , 2012, Pediatric Cardiology.
[12] Song-Bin Yang,et al. Copeptin is associated with mortality in patients with traumatic brain injury. , 2011, The Journal of trauma.
[13] P. Ponikowski,et al. Increased 90-Day Mortality in Patients With Acute Heart Failure With Elevated Copeptin: Secondary Results From the Biomarkers in Acute Heart Failure (BACH) Study , 2011, Circulation. Heart failure.
[14] N. Morgenthaler,et al. Copeptin: a biomarker of cardiovascular and renal function. , 2010, Congestive heart failure.
[15] N. Morgenthaler,et al. The vasopressin and copeptin response to infection, severe sepsis, and septic shock* , 2009, Critical care medicine.
[16] M. Konstam,et al. Arginine Vasopressin Antagonists for the Treatment of Heart Failure and Hyponatremia , 2008, Circulation.
[17] J. Struck,et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. , 2008, Journal of the American College of Cardiology.
[18] E. Braunwald,et al. Biomarkers in heart failure. , 2008, The New England journal of medicine.
[19] J. Struck,et al. Copeptin: clinical use of a new biomarker , 2008, Trends in Endocrinology & Metabolism.
[20] K. Swedberg,et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. , 2007, JAMA.
[21] J. Struck,et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure , 2006, European journal of clinical investigation.
[22] S. Colan,et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. , 2006, JAMA.
[23] J. Towbin,et al. Arginine Vasopressin Levels Are Elevated and Correlate With Functional Status in Infants and Children With Congestive Heart Failure , 2004, Circulation.
[24] J. Ghali,et al. Acute Hemodynamic Effects of Conivaptan, a Dual V1A and V2 Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure , 2001 .
[25] K. Kikuchi,et al. Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor. , 2000, European journal of pharmacology.
[26] M. Packer. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. , 1992, Journal of the American College of Cardiology.
[27] S. Yusuf,et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). , 1990, Circulation.
[28] K. Swedberg,et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. , 1990, Circulation.
[29] J. Cohn,et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.
[30] J. Cohn,et al. Increased plasma arginine vasopressin levels in patients with congestive heart failure. , 1983, Journal of the American College of Cardiology.
[31] N. Hollenberg,et al. Relation of the Renin‐Angiotensin-Aldosterone System to Clinical State in Congestive Heart Failure , 1981, Circulation.
[32] W. Chung,et al. Pediatric Cardiomyopathies. , 2017, Circulation research.
[33] Gail D Pearson,et al. Heart failure in children: part I: history, etiology, and pathophysiology. , 2009, Circulation. Heart failure.
[34] Michael Burch,et al. New-Onset Heart Failure Due to Heart Muscle Disease in Childhood: A Prospective Study in the United Kingdom and Ireland , 2008, Circulation.